Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Changing Realities in Treating mCRC

July 15th 2019

Future Directions in I/O Therapy for mCRC

July 10th 2019

Immunotherapy in CRC

July 10th 2019

Salvage Therapy for mCRC

July 10th 2019

New Therapy Options for BRAF-Mutated mCRC

July 10th 2019

Maintenance Therapy for mCRC

July 10th 2019

Management of Colorectal Cancer Metastases

July 10th 2019

Colon Cancer in Young Patients

July 10th 2019

TRIBE-2: FOLFOX or FOLFIRI With Bevacizumab in mCRC

July 10th 2019

Frontline Therapy for mCRC

July 10th 2019

Molecular Testing in 2019 for mCRC

July 10th 2019

Changing Paradigms for Rectal Cancer

July 10th 2019

IDEA Collaboration; Impact on Adjuvant Therapy

July 10th 2019

Adjuvant Treatment or "Watch and Wait" in Stage II CRC

July 10th 2019

Molecular Profiling in Stage II and III Colon Cancer

July 10th 2019

Adjuvant Therapy for Stage II and III Colon Cancer

July 10th 2019

SM-88 Shows Encouraging Survival Trends in Advanced Pancreatic Cancer

July 10th 2019

The oral modified dysfunctional tyrosine SM-88 demonstrated a median overall survival of 6.4 months in patients with advanced pancreatic cancer.

FDA Approval Sought for Extended Pembrolizumab Dosing Schedule for Select Indications

July 9th 2019

The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.

Encorafenib, Binimetinib, and Cetuximab Regimen Improves Survival in BRAF+ CRC

July 6th 2019

Encorafenib, binimetinib, and cetuximab demonstrated a significant improvement in overall survival compared with cetuximab and an irinotecan-containing regimen in patients with BRAF-mutant colorectal cancer.

Clinical Factors Help Define Use of Radionuclide Therapy in Neuroendocrine Tumors

July 5th 2019

Radiopharmaceuticals have been integrated into the treatment paradigm for patients with neuroendocrine tumors, yet there are nuances in the clinical scenarios in which they are most effective.